

Contents of volume 71

Regular papers

- M.N. Prichard, A.D. Williams, K.A. Keith, E.A. Harden, E.R. Kern*
Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus contribute significantly to the differential antiviral activity of nucleoside analogs 1
- T.M.C. Tan, Y. Chen, K.H. Kong, J. Bai, Y. Li, S.G. Lim, T.H. Ang, Y. Lam*
Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents 7
- S. de Castro, C. García-Aparicio, K. Van Laethem, F. Gago, E. Lobatón, E. De Clercq, J. Balzarini, M.-J. Camarasa, S. Velázquez*
Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile 15
- D.C. Quenelle, K.A. Keith, E.R. Kern*
In vitro and in vivo evaluation of isatin- β -thiosemicarbazone and marboran against vaccinia and cowpox virus infections 24
- Y.-Y. Xie, X.-D. Zhao, L.-P. Jiang, H.-L. Liu, L.-J. Wang, P. Fang, K.-L. Shen, Z.-D. Xie, Y.-P. Wu, X.-Q. Yang*
Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme) 31
- R.M. Kagan, P.K. Cheung, T.K. Huard, M.A. Lewinski*
Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment 42
- D.L. Barnard, C.W. Day, K. Bailey, M. Heiner, R. Montgomery, L. Lauridsen, S. Winslow, J. Hoopes, J.K.-K. Li, J. Lee, D.A. Carson, H.B. Cottam, R.W. Sidwell*
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin 53

Short communications

- V.P. Mishin, F.G. Hayden, K.L. Signorelli, L.V. Gubareva*
Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection 64
- A.S. Veiga, M.A.R.B. Castanho*
The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation 69

Editorial

- J. Balzarini, G. Andrei, L. Naesens, J. Neyts, C. Pannecouque, D. Schols, R. Snoeck*
Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven 75

Mini-reviews

- R. Pauwels*
Aspects of successful drug discovery and development 77
- B. Öberg*
Rational design of polymerase inhibitors as antiviral drugs 90

<i>G. Andrei</i> Three-dimensional culture models for human viral diseases and antiviral drug development	96
<i>A. Billiau</i> Anti-inflammatory properties of Type I interferons	108
<i>D.D. Richman</i> Antiviral drug resistance	117
<i>S.F. Wnuk, M.J. Robins</i> Ribonucleotide reductase inhibitors as anti-herpes agents	122
<i>H.J. Field, S. Biswas, I.T. Mohammad</i> Herpesvirus latency and therapy—From a veterinary perspective	127
<i>B. Golankiewicz, T. Ostrowski</i> Tricyclic nucleoside analogues as antiherpes agents	134
<i>R.J. Whitley</i> Herpes simplex encephalitis: Adolescents and adults	141
<i>C. McGuigan, J. Balzarini</i> Aryl furano pyrimidines: The most potent and selective anti-VZV agents reported to date	149
<i>K.K. Biron</i> Antiviral drugs for cytomegalovirus diseases	154
<i>E.R. Kern</i> Pivotal role of animal models in the development of new therapies for cytomegalovirus infections	164
<i>L. Lenaerts, L. Naesens</i> Antiviral therapy for adenovirus infections	172
<i>R. Snoeck</i> Papillomavirus and treatment	181
<i>P.D. Griffiths</i> Antivirals in the transplant setting	192
<i>X. Fan, X. Zhang, L. Zhou, K.A. Keith, E.R. Kern, P.F. Torrence</i> Assembling a smallpox biodefense by interrogating 5-substituted pyrimidine nucleoside chemical space	201
<i>F. Zoulim</i> Antiviral therapy of chronic hepatitis B	206
<i>D. Schols</i> HIV co-receptor inhibitors as novel class of anti-HIV drugs	216
<i>M.N. Preobrazhenskaya, E.N. Olsufyeva</i> Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry	227
<i>J. Balzarini</i> Inhibition of HIV entry by carbohydrate-binding proteins	237
<i>A. Holý</i> Antiviral acyclic nucleoside phosphonates structure activity studies	248
<i>W.A. Lee, J.C. Martin</i> Perspectives on the development of acyclic nucleotide analogs as antiviral drugs	254
<i>M.-J. Camarasa, S. Velázquez, A. San-Félix, M.-J. Pérez-Pérez, F. Gago</i> Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes?	260

<i>V.E. Marquez, S.H. Hughes, S. Sei, R. Agbaria</i> The history of N-methanocarbathymidine: The investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent	268
<i>C. Mathé, G. Gosselin</i> L-Nucleoside enantiomers as antiviral drugs: A mini-review	276
<i>C. Meier, J. Balzarini</i> Application of the <i>cycloSal</i> -prodrug approach for improving the biological potential of phosphorylated biomolecules	282
<i>C.F. Perno, V. Svirch, D. Schols, M. Pollicita, J. Balzarini, S. Aquaro</i> Therapeutic strategies towards HIV-1 infection in macrophages	293
<i>M. Baba</i> Recent status of HIV-1 gene expression inhibitors	301
<i>A. Van Aerschot</i> Oligonucleotides as antivirals: Dream or realistic perspective?	307
<i>P. Herdewijn</i> The interplay between antiviral activity, oligonucleotide hybridisation and nucleic acids incorporation studies	317
<i>R.F. Schinazi, B.I. Hernandez-Santiago, S.J. Hurwitz</i> Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses	322
<i>J. Vercauteren, A.-M. Vandamme</i> Algorithms for the interpretation of HIV-1 genotypic drug resistance information	335
<i>J. Martinez, P. Coplan, M.A. Wainberg</i> Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?	343
<i>Z. Huang, M.G. Murray, J.A. Secrist III</i> Recent development of therapeutics for chronic HCV infection	351
<i>J. Neyts</i> Selective inhibitors of hepatitis C virus replication	363
<i>F.G. Hayden</i> Antivirals for influenza: Historical perspectives and lessons learned	372
<i>R.W. Sidwell, D.L. Barnard</i> Respiratory syncytial virus infections: Recent prospects for control	379
<i>A.K. Patick</i> Rhinovirus chemotherapy	391
<i>B.L. Haagmans, A.D.M.E. Osterhaus</i> Coronaviruses and their therapy	397
Author Index	404
Subject Index	406
Volume Contents	412